证券代码：688566 证券简称：吉贝尔 公告编号：2023-034 江苏吉贝尔药业股份有限公司 关于参加 2023 年半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （一）会议线上交流时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 （二）会议召开方式：视频和线上文字互动 （三）视频和网路文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日（星期三）16:00 前通过邮件、电话等形式将 需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关 注的问题进行回答。 江苏吉贝尔药业股份有限公司（ ...

独立董事候选人声明与承诺 本人何娣, 已充分了解并同意由提名人江苏吉贝尔药业股份有限 公司董事会提名为江苏吉贝尔药业股份有限公司第四届董事会独立 董事候选人。本人公开声明，本人具备独立董事任职资格，保证不存 在任何影响本人担任江苏吉贝尔药业股份有限公司独立董事独立性 的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定; （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用); （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； (一) 在上市公司或者其附属企业任职的人员及其直系亲属和主 要社会关系（直系亲属是指配偶、父母、子女等；主要社会关系是指 兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的 配偶、子女配偶的父母等)； （二）直接或者间接持有上市公司已 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2023-015 江苏吉贝尔药业股份有限公司 关于参加 2022 年度集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 6 月 14 日（星期三）下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 2023 年 6 月 13 日（星期二）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍 关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日 在上海证券交易所网站（www.sse.com.cn）发布《公司 2022 年年度报告》，为便 于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况、发展理念， 公司参与了由上海证券交易所主办的 2022 年度 ...

Financial Performance - The company's operating revenue for 2022 was ¥654,730,646.35, representing a year-on-year increase of 28.46% compared to ¥509,693,982.77 in 2021 [25]. - The net profit attributable to shareholders of the listed company was ¥154,667,820.31, up 34.61% from ¥114,901,343.14 in the previous year [25]. - The basic earnings per share for 2022 was ¥0.83, reflecting a 36.07% increase from ¥0.61 in 2021 [26]. - The net cash flow from operating activities was ¥150,724,074.86, showing a slight increase of 0.11% compared to ¥150,556,993.47 in 2021 [25]. - The total assets at the end of 2022 were ¥1,964,575,110.90, an increase of 8.02% from ¥1,818,686,866.85 at the end of 2021 [25]. - The company's net assets attributable to shareholders at the end of 2022 were ¥1,688,429,785.82, a 5.40% increase from ¥1,601,985,101.69 at the end of 2021 [25]. - The company's cash flow from operating activities was approximately ¥150.72 million, showing a slight increase of 0.11% compared to the previous year [139]. - The company reported a significant increase in production volume for Nifedipine Tablets, up 112.53% year-over-year, while sales volume increased by 25.46% [144]. Research and Development - The company's R&D investment as a percentage of operating revenue was 8.43%, up from 5.75% in the previous year, indicating a focus on innovation [27]. - The total R&D investment for the year reached ¥55,180,366.07, an increase of 88.44% compared to ¥29,282,498.21 in the previous year, with R&D expenses accounting for 8.43% of total revenue [99][100]. - The company is developing a new antidepressant drug JJH201501, which has shown significant antidepressant effects and improved learning and memory in Phase I clinical trials, currently progressing to Phase IIb trials [58]. - The anti-tumor drug JJH201601 has demonstrated superior tumor suppression effects compared to imported docetaxel injection in various models, with lower side effects, and is moving forward with Phase I clinical trials [59]. - The company has established a comprehensive drug development system, focusing on patient needs and clinical value, supported by a professional R&D team and various research departments [65]. - The company is actively pursuing clinical trials for multiple new drugs, including JJH201501 and JJH201601, indicating a robust pipeline for future growth [101]. - The company has established a research and development platform focusing on compound formulations, deuterated drugs, and liposome drug technologies [169]. - Major R&D projects included JJH201501 and JJH201601, with respective investments of CNY 1,765.12 million and CNY 1,846.51 million, reflecting year-on-year increases of 165.82% and 99.29% [182]. Market and Product Development - The company attributed its strong performance to enhanced product channel construction and market development efforts, leading to rapid sales growth [27]. - The company's main products include tablets, capsules, and eye drops, with key products like Licorice Tablets and Nifedipine Tablets being recognized as essential medications in their respective categories [47][49]. - Licorice Tablets have been included in the National Basic Medical Insurance Directory (2022) and are widely used in thousands of hospitals across China, demonstrating a strong market presence [48]. - The company’s main product, Likujun tablets, is a leading drug in the leukocyte-boosting category, widely used in various medical fields, ensuring a strong market share [77]. - The company is actively expanding its marketing system and has established dedicated departments to enhance academic support and business operations [70]. - The company has established a comprehensive marketing network across China, enhancing product promotion through expert networks and academic outreach, effectively covering major target markets [117]. Governance and Compliance - The company has received a standard unqualified audit report from Xinyong Zhonghe Accounting Firm [5]. - The company has confirmed that all board members were present at the board meeting [5]. - The board of directors consists of 7 members, including 3 independent directors, ensuring effective governance and compliance with legal requirements [199]. - The company has established a supervisory board with three members, including a representative from employees, to protect shareholder rights and interests [200]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees [10]. - The company has not reported any special arrangements in corporate governance [10]. Risks and Challenges - The company is currently facing risks related to new drug development, including potential delays in obtaining clinical trial approvals for its innovative drugs [124]. - The company’s main product, Li Ke Jun, has multiple layers of technical barriers, but faces risks from potential imitation or substitution by other pharmaceutical companies [123]. - The company relies heavily on the revenue from its main product, Likujun tablets, which poses a risk if faced with increased competition or changes in the operating environment [127]. - The company faces risks related to the approval of new drug applications, which may not meet expectations due to long development cycles and regulatory uncertainties [127]. - The company is exposed to credit risk, with accounts receivable and notes receivable totaling approximately ¥216.21 million, accounting for 17.2% of current assets [132]. - The company is at risk of price reductions due to national drug procurement policies, which could impact revenue and profitability if its main products are included in procurement lists [135]. - The company is actively monitoring macroeconomic risks and is prepared to implement measures to mitigate potential impacts on its business [136]. Talent and Human Resources - A total of 263 talents were recruited during the reporting period, including 102 with a bachelor's degree or higher, supporting the company's high-quality development [45]. - The R&D personnel count is 101, accounting for 9.94% of the total workforce, with an average salary of CNY 175,756.98 [112]. - The company has conducted 127 training sessions throughout the year, with over 1,400 participants, to foster talent development and retention [45]. - The company is committed to talent acquisition and development, establishing a robust human resources management system to foster innovation and enhance team capabilities [196]. Production and Operations - The company has completed the construction of over 30,000 square meters of production facilities, including a comprehensive formulation workshop and two specialized workshops, enhancing its competitive advantage in the industry [42]. - The company maintains a production model based on planned production, ensuring adequate inventory to meet market demand while adhering to GMP certification standards [70]. - The procurement department manages the supply of raw materials and packaging, ensuring quality through supplier audits and maintaining safety stock levels [66]. - The company has implemented internal control systems for procurement and supplier evaluation, ensuring compliance and effective execution during the reporting period [68]. - The company is advancing the construction of production and R&D centers to enhance capacity and support clinical research for its anti-tumor drug JJH201601 [195].

Financial Performance - The company's operating revenue for Q1 2023 was ¥165,341,239.75, representing a year-on-year increase of 19.10%[5] - The net profit attributable to shareholders for the same period was ¥38,010,611.11, reflecting a growth of 32.98% compared to the previous year[5] - Basic and diluted earnings per share both stood at ¥0.20, up by 33.33% from the previous year[5] - Total revenue for Q1 2023 reached ¥165,341,239.75, an increase of 19.06% compared to ¥138,822,101.80 in Q1 2022[20] - Operating profit for Q1 2023 was ¥40,125,232.79, up from ¥32,539,476.75 in Q1 2022, reflecting a growth of 23.88%[20] - Net profit for Q1 2023 was ¥37,907,684.96, compared to ¥28,472,006.74 in Q1 2022, representing a year-over-year increase of 33.24%[21] - Earnings per share for Q1 2023 were ¥0.20, up from ¥0.15 in Q1 2022, indicating a growth of 33.33%[21] - Cash flow from operating activities for Q1 2023 was ¥102,656,045.82, significantly higher than ¥17,129,889.13 in Q1 2022[22] - Total operating costs for Q1 2023 were ¥122,667,342.99, an increase of 15.59% from ¥106,108,841.42 in Q1 2022[20] - The company reported a decrease in income tax expenses to ¥2,055,745.20 in Q1 2023 from ¥4,044,601.59 in Q1 2022, a reduction of 49.32%[21] Cash Flow and Assets - The net cash flow from operating activities surged to ¥102,656,045.82, marking an impressive increase of 499.28% year-on-year[5] - Cash inflow from operating activities totaled ¥238,889,526.09 in Q1 2023, compared to ¥144,454,113.86 in Q1 2022, marking an increase of 65.41%[22] - The total assets at the end of the reporting period were ¥1,964,513,238.45, showing no significant change from the previous year[6] - As of March 31, 2023, the total current assets amounted to RMB 1,111,541,817.52, a decrease from RMB 1,256,773,525.38 at the end of 2022, reflecting a decline of approximately 11.5%[15] - The total non-current assets increased to RMB 852,971,420.93 from RMB 707,801,585.52, representing a growth of about 20.5%[16] - The total liabilities decreased to RMB 226,867,592.85 from RMB 270,244,965.69, indicating a reduction of approximately 16.1%[16] - The cash and cash equivalents were reported at RMB 722,824,564.93, down from RMB 903,903,294.77, which is a decline of around 20%[15] - The ending balance of cash and cash equivalents as of Q1 2023 was $722.49 million, up from $506.57 million in the same period last year[23] Shareholder Information - The equity attributable to shareholders increased by 2.57% to ¥1,731,848,212.37 compared to the end of the previous year[6] - The company reported a total of 7,544 common shareholders at the end of the reporting period[10] - The total equity remained stable at RMB 1,737,645,645.60, with no significant changes reported[16] Research and Development - Research and development expenses totaled ¥8,534,363.18, accounting for 5.16% of operating revenue, which is an increase of 0.10 percentage points[6] - Research and development expenses for Q1 2023 amounted to ¥8,534,363.18, up from ¥7,028,935.99 in Q1 2022, reflecting a growth of 21.41%[20] Non-Recurring Items and Other Information - Non-recurring gains and losses amounted to ¥280,851.05, after accounting for tax effects[7] - The weighted average return on net assets was 2.22%, an increase of 0.46 percentage points[5] - The company did not participate in any financing or margin trading activities during the reporting period[13] - There were no new product launches or technological advancements mentioned in the report[14] - The company has not disclosed any plans for market expansion or mergers and acquisitions in the near future[14] - The net cash flow from investing activities for Q1 2023 was -$280.67 million, compared to -$525.26 million in Q1 2022, indicating an improvement[23] - The total cash outflow from financing activities was $865,166.39, with a net cash flow from financing activities of $295,018.61[23] - The net increase in cash and cash equivalents for Q1 2023 was -$177.72 million, compared to -$508.13 million in Q1 2022, showing a reduction in cash burn[23] - The company has implemented new accounting standards starting in 2023, which may affect financial reporting[23]

Financial Performance - The company's operating revenue for Q3 2022 was ¥169,358,593.98, representing a 45.97% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,145,036.54, reflecting an 80.32% increase year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,124,049.42, showing a significant increase of 112.45% compared to the previous year[5] - Basic and diluted earnings per share for Q3 2022 were both ¥0.20, an increase of 81.82% from the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached CNY 426,569,744.86, an increase of 16.3% compared to CNY 366,826,002.01 in the same period of 2021[22] - Net profit for the third quarter of 2022 was CNY 78,942,288.10, representing a 4.0% increase from CNY 75,820,535.26 in the same quarter of 2021[23] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.42, compared to CNY 0.41 in the same quarter of 2021[24] Research and Development - The total R&D investment for Q3 2022 was ¥12,648,235.91, which is an 85.05% increase year-over-year[6] - R&D investment accounted for 7.47% of operating revenue in Q3 2022, up by 1.58 percentage points compared to the previous year[6] - Research and development expenses for new drugs increased by 75.68% year-on-year, totaling RMB 41,833,870.00[15] - Research and development expenses for the first three quarters of 2022 totaled CNY 41,833,870.00, significantly higher than CNY 23,813,200.62 in the same period of 2021, indicating a focus on innovation[22] - The company is advancing the development of new drugs JJH201501 and JJH201601[15] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,883,772,433.02, a 3.58% increase from the end of the previous year[6] - Total assets as of September 30, 2022, amounted to RMB 1,883,772,433.02, compared to RMB 1,818,686,866.85 at the end of 2021[19] - Total liabilities as of the end of the third quarter of 2022 amounted to CNY 269,935,507.78, an increase from CNY 210,396,612.27 at the end of the previous year[21] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,607,846,151.63, reflecting a slight increase of 0.37% from the previous year[6] - Total equity attributable to shareholders of the parent company was CNY 1,607,846,151.63, a slight increase from CNY 1,601,985,101.69 in the previous year[21] Cash Flow - The cash flow from operating activities for the year-to-date was ¥103,504,097.97, representing a 4.42% increase[6] - Net cash flow from operating activities was $103,504,097.97, an increase from $99,120,817.12 in the previous year, reflecting a growth of approximately 3.8%[26] - Cash inflow from investment activities totaled $1,117,618,312.08, down from $1,387,683,406.62, indicating a decrease of about 19.5% year-over-year[27] - Total cash and cash equivalents at the end of the period stood at $760,789,488.56, compared to $460,138,487.63 at the end of the same quarter last year, representing an increase of approximately 65.2%[27] - The net increase in cash and cash equivalents for the period was -$253,920,254.49, compared to -$826,895,200.08 in the same quarter last year, showing a significant improvement[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,038[13] - The largest shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 54,400,000 shares, accounting for 29.10% of total shares[13] Legal and Other Matters - The company is currently involved in a legal dispute with Hubei Jiuzhoutong and has filed a counterclaim[16] - The company has implemented a stock incentive plan, granting 7.33 million restricted shares at a price of RMB 12.30 per share[15] - The company’s inventory increased to RMB 33,425,671.52 from RMB 31,825,596.70 year-on-year[19] - The company’s long-term equity investments decreased to RMB 52,045,854.00 from RMB 56,625,042.03[19] - The company reported a decrease in unallocated profits to CNY 301,650,497.89 from CNY 320,147,417.75 in the same period last year[21] - The company experienced a significant increase in other payables, which rose to CNY 76,132,821.76 from CNY 20,278,559.67 in the previous year[21]

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 257,211,150.88, representing a 2.56% increase compared to RMB 250,803,104.55 in the same period last year[19]. - The net profit attributable to shareholders decreased by 24.33% to RMB 42,111,630.84 from RMB 55,649,582.17 year-on-year[19]. - The net profit after deducting non-recurring gains and losses fell by 34.84% to RMB 30,866,460.74 compared to RMB 47,368,235.14 in the previous year[19]. - The net cash flow from operating activities increased by 18.76% to RMB 66,217,847.68 from RMB 55,756,491.97 in the same period last year[19]. - The company's total assets as of June 30, 2022, were RMB 1,838,075,765.52, a 1.07% increase from RMB 1,818,686,866.85 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 0.51% to RMB 1,610,104,975.76 from RMB 1,601,985,101.69 at the end of the previous year[19]. - Basic earnings per share decreased by 23.33% to RMB 0.23 from RMB 0.30 in the same period last year[21]. - The company reported a total revenue of 97,325.00 million RMB for the first half of 2022, with a net profit of 2,801.44 million RMB, representing a significant increase of 17,149.90 million RMB compared to the previous year[88]. Research and Development - The R&D investment accounted for 11.35% of operating revenue, an increase of 4.58 percentage points from 6.77% in the previous year[21]. - The company has increased its R&D investment significantly, with a total R&D expenditure of ¥29,185,634.09, representing a 71.90% increase compared to the previous year[77]. - The company is actively developing new drugs, including JJH201501 for depression, JJH201601 for cancer, and JJH201701 for gastric acid-related issues, among others, enhancing its product pipeline[93]. - The company has established a comprehensive drug research and development system, focusing on patient needs and clinical value, supported by a professional R&D team[53]. - The company is focusing on liposome drug delivery technology, which enhances drug targeting and stability[74]. - The company has developed several new drugs, including JJH201501, an antidepressant currently in Phase IIb clinical trials, showing improved pharmacokinetics and efficacy[43]. - The company is also developing JJH201601, a novel anti-tumor drug, utilizing liposome technology and preparing for clinical application submission[44]. - The company has received recognition as a provincial engineering technology research center with excellent performance in Jiangsu Province[75]. Market Position and Products - The company specializes in drug research and development across multiple therapeutic areas, including treatments for cancer and depression[25]. - The company's main products include tablets, capsules, and eye drops, with a focus on innovative drug development[28]. - The company’s product, Likujun tablets, is recognized for its efficacy in treating leukopenia and has been included in the National Basic Medical Insurance Directory[31]. - The company holds a unique position as the only domestic and international producer of Likujun raw materials and tablets, supported by patented technology[31]. - The company has launched the first compound antihypertensive drug, Nigunol Tablets, which is included in the National Basic Medical Insurance Directory (2021) and recommended in multiple hypertension treatment guidelines[33]. - The company is the sole manufacturer of Nigunol Tablets, with no generic versions available in the market, ensuring a unique market position[33]. - The company’s main product, Likujun tablets, holds a leading market share in oral leukocyte-increasing drugs, effectively treating leukopenia and thrombocytopenia[61]. - The company is increasing marketing efforts for its antihypertensive drug, Nigulol tablets, which uniquely lowers both blood pressure and heart rate, aiming for stable revenue growth[61]. Corporate Governance and Compliance - The report emphasizes that the financial report is guaranteed to be true, accurate, and complete by the responsible personnel[5]. - The board of directors has confirmed that all members attended the meeting, ensuring accountability[3]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a dedicated department for the operation and maintenance of wastewater treatment and air pollution control facilities, ensuring normal operation without major environmental issues[152]. - The company has recognized key technical personnel in drug research and development, including project leaders and main members of research institutes[145]. - The company has a valid wastewater discharge permit obtained in May 2021, valid for five years, ensuring compliance with environmental regulations[153]. - The company has implemented strict GMP standards in its production processes, ensuring product quality and compliance with pharmaceutical standards[100]. - The company has successfully maintained a record of zero quality and safety incidents during the reporting period[103]. Risks and Challenges - The decrease in net profit was primarily due to increased investment in new drug research and development and the stock-based compensation expenses related to the 2021 restricted stock incentive plan[21]. - The company faces risks related to the inability to obtain clinical trial approvals for its innovative drugs currently in preclinical research, with only JJH201501 having entered clinical trials[116]. - The company’s revenue heavily relies on the product Likujun tablets, which poses a risk if competition increases or market conditions change[118]. - The company is exposed to potential price reductions due to national drug procurement policies, which could significantly impact revenue and profitability[125]. - The company benefits from a reduced corporate income tax rate of 15% as a high-tech enterprise, but risks losing this status could adversely affect financial performance[126]. Environmental Responsibility - The company’s emissions of non-methane total hydrocarbons and nitrogen oxides are within the acceptable limits, demonstrating compliance with environmental standards[151]. - The company has made commitments regarding share lock-up periods, ensuring no share transfers for a specified duration post-IPO[161]. - The company is committed to social responsibility by promoting technological innovation and energy conservation, with all waste emissions consistently meeting regulatory standards[157]. - The company has a complete set of environmental protection documents, including administrative permits and emergency response plans, ensuring compliance with environmental laws and regulations[157]. - The company has implemented an environmental self-monitoring plan, ensuring that all pollutant indicators meet discharge standards as verified by a qualified third-party testing agency[155]. Shareholder Commitments - The company commits to increasing R&D investment and developing new products to meet customer demands[187]. - The company aims to enhance operational efficiency and profitability through improved management and internal controls[187]. - The controlling shareholder and actual controller commit to not interfering with the company's management activities[187]. - The company will publicly explain any failure to fulfill commitments and apologize to shareholders and investors[195]. - The company will bear full responsibility for any compensation payments resulting from legal disputes[19].

Financial Performance - The company's operating revenue for 2021 was approximately ¥509.69 million, a decrease of 9.94% compared to ¥565.97 million in 2020[23]. - The net profit attributable to shareholders for 2021 was approximately ¥114.90 million, down 11.42% from ¥129.72 million in 2020[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥93.18 million, a decrease of 18.34% compared to ¥114.10 million in 2020[23]. - Basic earnings per share decreased by 20.78% to 0.61 yuan per share compared to 2020[25]. - The weighted average return on equity fell by 4.40 percentage points to 7.22% in 2021[25]. - The gross profit margin for the pharmaceutical manufacturing segment was 87.81%, a decrease of 0.87 percentage points compared to the previous year[145]. - Sales of the main product, Likujun tablets, generated revenue of ¥378,463,930.34, a decline of 17.07% year-on-year[145]. - The company reported a total revenue of 97,325,000 RMB, with a net profit of 2,643,020 RMB for the year 2021[112]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.40 per 10 shares, totaling RMB 44,865,984.00 (including tax) for the 2021 fiscal year[7]. - The total cash dividends for 2021 will amount to RMB 89,731,968.00 (including tax), representing 78.09% of the net profit attributable to shareholders[8]. Audit and Governance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[6]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not reported any special arrangements for corporate governance[9]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[10]. Research and Development - The total R&D expenditure for the year was approximately ¥29.28 million, a decrease of 12.71% compared to the previous year[107]. - R&D expenditure accounted for 5.75% of the company's total revenue, down from 5.93% in the previous year, representing a decrease of 0.18 percentage points[107]. - The company is developing several new drugs, including JJH201501 for depression and JJH201601 for cancer treatment, among others[117]. - The company has a pipeline of innovative drugs, including Lifitegrast derivatives for dry eye treatment and JBE-01 for anesthesia and analgesia, currently in preclinical stages[173]. - The company has not canceled any major R&D projects or failed to obtain approvals for any products during the reporting period[174]. Market and Industry Trends - The global pharmaceutical market reached $1,298.8 billion in 2020, with a projected CAGR of 5.7% to reach $1,711.4 billion by 2025[76]. - The Chinese pharmaceutical market is expected to grow at a CAGR of 9.6% over the next five years, reaching ¥2,991.1 billion by 2030[79]. - The pharmaceutical industry is expected to benefit from multiple factors, including an aging population and health consumption upgrades, leading to promising development opportunities in the future[82]. Product Development and Innovation - The company is actively advancing new drug research, with several candidates in various stages of clinical trials, including JJH201501 for depression, which is currently in Phase IIb trials[45]. - The company has successfully expanded the sales of its product, Nicergoline tablets, across 26 provinces in China, contributing to stable revenue growth[42]. - The company has developed a new antidepressant drug JJH201501, which is currently in the IIb clinical trial phase after completing Phase I trials and has received patent authorization in China, the US, and Europe[171]. - The oncology drug JJH201601 is preparing to submit for clinical application after completing pharmacological and toxicological studies[172]. Risks and Challenges - The company has detailed various risks faced in its production and operation processes in the report[5]. - The company faces risks related to the potential for its main products to be included in centralized procurement lists, which could lead to significant price reductions and impact profitability[139]. - The company is exposed to risks from potential breakthroughs in the treatment areas of its pipeline drugs, which could lead to competitive pressures[128]. Marketing and Sales Strategy - The company has established a comprehensive marketing network across all provinces in China, enhancing the promotion of its key products[43]. - The marketing network covers over 20,000 hospitals and medical institutions nationwide, including 65 of the top 100 chain pharmacies[120]. - The company intends to increase the market promotion efforts for existing products like Likujun tablets and Nifedipine tablets to capture untapped market segments[200]. Financial Position and Assets - As of the end of 2021, the net assets attributable to shareholders were approximately ¥1.60 billion, an increase of 2.07% from ¥1.57 billion at the end of 2020[23]. - Total assets reached 1.8186869 billion yuan, with net assets attributable to shareholders at 1.6019851 billion yuan by the end of 2021[38]. - Accounts receivable and notes receivable totaled CNY 146.60 million, representing 10.43% of current assets and 28.76% of operating revenue, indicating potential credit risk as revenue grows[137].

Financial Performance - The company's operating revenue for Q1 2022 was ¥138,822,101.80, representing a year-on-year increase of 15.61%[3] - The net profit attributable to shareholders for the same period was ¥28,584,367.50, reflecting a growth of 5.95% compared to the previous year[3] - The basic and diluted earnings per share were both ¥0.15, up by 7.14% year-on-year[3] - The company achieved operating revenue of RMB 138.82 million, representing a year-on-year growth of 15.61%[10] - The net profit attributable to shareholders was RMB 28.58 million, with a year-on-year increase of 5.95%[10] - The company's total comprehensive income for Q1 2022 was CNY 28,472,006.74, up from CNY 26,763,907.49 in Q1 2021[17] - The net profit for Q1 2022 reached CNY 28,472,006.74, representing a 6.4% increase from CNY 26,763,907.49 in Q1 2021[16] - The net profit for Q1 2022 was CNY 29,956,319.22, representing a growth of 14.67% from CNY 26,178,742.13 in Q1 2021[24] Cash Flow - The net cash flow from operating activities decreased by 7.07% to ¥17,129,889.13[3] - In Q1 2022, the company's net cash flow from operating activities was ¥21,049,508.91, a significant improvement compared to a net outflow of ¥6,263,744.38 in Q1 2021[26] - The company reported a decrease in cash flow from financing activities, resulting in a net cash decrease of CNY 508,134,903.65 for Q1 2022[19] - The company incurred cash payments for operating activities totaling ¥122,144,783.82 in Q1 2022, down from ¥159,105,892.23 in Q1 2021, a decrease of about 23.2%[26] - The company reported a total cash outflow from investing activities of ¥746,393,802.84 in Q1 2022, compared to ¥1,106,788,634.35 in the same period of 2021, indicating a reduction of about 32.5%[27] - The net cash flow from investment activities for Q1 2022 was -CNY 525,264,792.78, compared to -CNY 1,116,788,634.35 in the same period last year[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,829,821,119.93, showing a slight increase of 0.61% from the end of the previous year[4] - As of March 31, 2022, total assets amounted to RMB 1.83 billion, slightly up from RMB 1.82 billion at the end of 2021[12] - Current assets totaled RMB 1.37 billion, a decrease from RMB 1.41 billion at the end of 2021[12] - The total liabilities decreased to RMB 187.65 million from RMB 210.40 million at the end of 2021[13] - The total liabilities as of March 31, 2022, were CNY 197,714,362.68, a decrease from CNY 214,190,743.20 at the end of 2021[23] - The company's total equity as of March 31, 2022, was CNY 1,623,621,540.65, up from CNY 1,588,253,117.54 at the end of 2021[24] Research and Development - Research and development expenses totaled ¥7,028,935.99, accounting for 5.06% of operating revenue, which is an increase of 0.51 percentage points year-on-year[4] - Research and development expenses for Q1 2022 totaled CNY 7,028,935.99, an increase of 28.9% from CNY 5,463,969.51 in Q1 2021[15] - The company recognized share-based payment expenses of RMB 5.41 million during the reporting period[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,893[8] - The largest shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., held 29.10% of the shares, totaling 54,400,000 shares[8] Other Financial Information - The company reported a government subsidy of ¥526,800.34 included in non-operating income[5] - The company experienced a foreign exchange loss of CNY 289,980.84 in Q1 2022, compared to a gain of CNY 641,176.23 in Q1 2021[16] - The company reported a decrease in tax expenses to CNY 4,044,601.59 from CNY 4,267,060.80 in Q1 2021[16] - The company’s sales expenses for Q1 2022 were CNY 70,370,702.30, an increase of 12.93% compared to CNY 62,438,781.15 in Q1 2021[24]

2021 年第三季度报告 证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 同期增减变 | | | | | | 动幅度(%) | | 营业收入 | 116,022,897.46 | -27.44 | 366,826,002.01 | -8.97 ...